| 5 mins | 30 mins | Hourly | Daily | Weekly |
|---|---|---|---|---|
| SELL | BUY | BUY | BUY | BUY |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MA5 | 12.87▼ | 12.80▲ | 12.81▲ | 12.58▲ | 12.44▲ |
| MA10 | 12.86▼ | 12.82▼ | 12.75▲ | 12.38▲ | 11.39▲ |
| MA20 | 12.82▼ | 12.72▲ | 12.65▲ | 12.25▲ | 9.76▲ |
| MA50 | 12.82▼ | 12.54▲ | 12.48▲ | 10.77▲ | 8.78▲ |
| MA100 | 12.74▲ | 12.46▲ | 12.24▲ | 9.43▲ | 7.70▲ |
| MA200 | 12.66▲ | 12.25▲ | 12.07▲ | 8.87▲ | 9.11▲ |
| 5 mins | 30 mins | Hourly | Daily | Weekly | |
|---|---|---|---|---|---|
| MACD | 0.003▲ | -0.001▼ | 0.011▲ | -0.037▼ | 0.378▲ |
| RSI | 48.096▼ | 58.243▲ | 61.071▲ | 68.857▲ | 75.917▲ |
| STOCH | 71.998 | 65.565 | 78.749 | 75.544 | 94.661▲ |
| WILL %R | -65.385 | -22.973▲ | -22.973▲ | -6.767▲ | -1.603▲ |
| CCI | -20.513 | 73.098 | 91.830 | 129.055▲ | 89.379 |
|
Monday, August 04, 2025 10:16 AM
Investors might want to bet on Aurinia Pharmaceuticals (AUPH), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which ...
|
|
Thursday, July 31, 2025 05:00 PM
Revenue (GAAP) grew 22% year over year to $70.0 million, beating GAAP expectations by nearly $6.2 million. Diluted earnings per share (GAAP) reached $0.16, above the analyst estimate and up from $0.01 ...
|
| date | open | high | low | close | volume |
|---|---|---|---|---|---|
| 15/09/25 | 12.75 | 12.90 | 12.53 | 12.81 | 1,177,088 |
| 12/09/25 | 12.72 | 12.87 | 12.53 | 12.74 | 1,369,185 |
| 11/09/25 | 12.29 | 12.78 | 12.1864 | 12.78 | 2,227,221 |
| 10/09/25 | 12.35 | 12.48 | 12.06 | 12.22 | 1,563,149 |
| 09/09/25 | 12.30 | 12.41 | 12.17 | 12.35 | 1,205,448 |
| 08/09/25 | 12.37 | 12.54 | 12.21 | 12.30 | 1,155,320 |
| 05/09/25 | 12.56 | 12.818 | 12.36 | 12.40 | 1,824,810 |
| 04/09/25 | 12.00 | 12.64 | 11.99 | 12.53 | 2,277,754 |
| 03/09/25 | 11.65 | 12.005 | 11.57 | 12.00 | 2,336,828 |
| 02/09/25 | 11.90 | 12.015 | 11.64 | 11.68 | 1,620,609 |
|
|
||||
|
|
||||
|
|